Exciting News from the MACUSTAR .eu Consortium

The European public-private partnership consortium MACUSTAR .eu has received a third 𝗟𝗲𝘁𝘁𝗲𝗿 𝗼𝗳 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 from the European Medicines Agency (EMA) for its efforts in developing novel outcome measures for clinical trials evaluating treatments for the common eye condition age-related macular degeneration (AMD).

The scientific advice by the agency was based on four-year study results of more than 𝟲𝟬𝟬 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻𝘀 𝘄𝗶𝘁𝗵 𝗲𝗮𝗿𝗹𝘆 𝘀𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗔𝗠𝗗 who are at a high risk of developing visual impairment. EMA recognises the high quality and impact of the scientific outputs from the 𝗠𝗔𝗖𝗨𝗦𝗧𝗔𝗥 project that may have impact on more than 200 million patients with AMD globally.

The MACUSTAR consortium unites 20 EVICR.net clinical centers across 7 European countries, with the clinical study sponsored by UKB University of Bonn and AIBILI-Association for Innovation and Biomedical Research on Light and Image as the clinical trial unit coordinator.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116076. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. A further funding from Bayer, Novartis and Roche enabled the study to be extended by three years.

Read the EMA’s Full Letter of Support here: Letter of Support for intermediate Age-Related Macular Degeneration (AMD) biomarker and novel clinical endpoint development